AU2019300038C1 - Self-assembling peptide scaffold - Google Patents

Self-assembling peptide scaffold Download PDF

Info

Publication number
AU2019300038C1
AU2019300038C1 AU2019300038A AU2019300038A AU2019300038C1 AU 2019300038 C1 AU2019300038 C1 AU 2019300038C1 AU 2019300038 A AU2019300038 A AU 2019300038A AU 2019300038 A AU2019300038 A AU 2019300038A AU 2019300038 C1 AU2019300038 C1 AU 2019300038C1
Authority
AU
Australia
Prior art keywords
peptide
hapten
oligomer
disease
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019300038A
Other languages
English (en)
Other versions
AU2019300038B2 (en
AU2019300038A1 (en
Inventor
Keith Douglas MILLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexamer Therapeutics Inc
Original Assignee
Hexamer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexamer Therapeutics Inc filed Critical Hexamer Therapeutics Inc
Publication of AU2019300038A1 publication Critical patent/AU2019300038A1/en
Publication of AU2019300038B2 publication Critical patent/AU2019300038B2/en
Priority to AU2023202175A priority Critical patent/AU2023202175A1/en
Application granted granted Critical
Publication of AU2019300038C1 publication Critical patent/AU2019300038C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019300038A 2018-07-12 2019-07-12 Self-assembling peptide scaffold Active AU2019300038C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202175A AU2023202175A1 (en) 2018-07-12 2023-04-11 Self-assembling peptide scaffold

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697132P 2018-07-12 2018-07-12
US62/697,132 2018-07-12
PCT/US2019/041601 WO2020014609A2 (en) 2018-07-12 2019-07-12 Self-assembling peptide scaffold

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202175A Division AU2023202175A1 (en) 2018-07-12 2023-04-11 Self-assembling peptide scaffold

Publications (3)

Publication Number Publication Date
AU2019300038A1 AU2019300038A1 (en) 2021-02-04
AU2019300038B2 AU2019300038B2 (en) 2023-01-12
AU2019300038C1 true AU2019300038C1 (en) 2024-01-04

Family

ID=69142622

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019300038A Active AU2019300038C1 (en) 2018-07-12 2019-07-12 Self-assembling peptide scaffold
AU2023202175A Pending AU2023202175A1 (en) 2018-07-12 2023-04-11 Self-assembling peptide scaffold

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202175A Pending AU2023202175A1 (en) 2018-07-12 2023-04-11 Self-assembling peptide scaffold

Country Status (12)

Country Link
US (2) US12458692B2 (https=)
EP (2) EP4218928A3 (https=)
JP (2) JP2021531337A (https=)
KR (1) KR20210065086A (https=)
CN (1) CN112512552B (https=)
AU (2) AU2019300038C1 (https=)
BR (1) BR112021000455A2 (https=)
CA (1) CA3105706A1 (https=)
MA (1) MA52591A (https=)
MX (1) MX2021000444A (https=)
WO (1) WO2020014609A2 (https=)
ZA (1) ZA202100952B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097923A2 (en) * 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
US20100305304A1 (en) * 2007-09-07 2010-12-02 Complix Nv Non-natural proteinaceous scaffold made of three non-covalently associated peptides
WO2013009971A1 (en) * 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2014126828A1 (en) * 2013-02-15 2014-08-21 Merck Sharp & Dohme Corp. Novel ph-switchable peptides for membrane insertion and pore formation
WO2015035475A1 (en) * 2013-09-16 2015-03-19 The University Of Queensland Silica micro- and nano-capsules and methods for making them
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
US20160122783A1 (en) * 2008-04-29 2016-05-05 Monsanto Technology Llc Genes and Uses for Plant Enhancement
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
EP1237930B1 (en) 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097923A2 (en) * 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
US20100305304A1 (en) * 2007-09-07 2010-12-02 Complix Nv Non-natural proteinaceous scaffold made of three non-covalently associated peptides
US20160122783A1 (en) * 2008-04-29 2016-05-05 Monsanto Technology Llc Genes and Uses for Plant Enhancement
WO2013009971A1 (en) * 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2014126828A1 (en) * 2013-02-15 2014-08-21 Merck Sharp & Dohme Corp. Novel ph-switchable peptides for membrane insertion and pore formation
WO2015035475A1 (en) * 2013-09-16 2015-03-19 The University Of Queensland Silica micro- and nano-capsules and methods for making them
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds

Also Published As

Publication number Publication date
BR112021000455A2 (pt) 2021-04-06
AU2023202175A1 (en) 2023-05-04
CN112512552A (zh) 2021-03-16
WO2020014609A4 (en) 2020-04-16
US12458692B2 (en) 2025-11-04
CN112512552B (zh) 2024-10-22
EP3826661A4 (en) 2022-08-31
ZA202100952B (en) 2023-10-25
AU2019300038B2 (en) 2023-01-12
JP2021531337A (ja) 2021-11-18
US20260061049A1 (en) 2026-03-05
EP4218928A3 (en) 2023-12-13
MX2021000444A (es) 2021-05-27
CA3105706A1 (en) 2020-01-16
WO2020014609A3 (en) 2020-02-20
MA52591A (fr) 2021-06-02
EP4218928A2 (en) 2023-08-02
EP3826661A2 (en) 2021-06-02
JP2024036461A (ja) 2024-03-15
US20210268105A1 (en) 2021-09-02
WO2020014609A2 (en) 2020-01-16
KR20210065086A (ko) 2021-06-03
AU2019300038A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20260061049A1 (en) Self-assembling peptide scaffold
JP2023524054A (ja) ベータコロナウイルスの予防と治療
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
JP7677953B2 (ja) 前立腺癌処置のための免疫治療薬
CN113329762A (zh) 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
CN108025059B (zh) 抗猫过敏的组合物
US11065317B2 (en) Heat shock protein-binding peptide compositions and methods of use thereof
US20230346920A1 (en) Vaccines against viral pathogens
CA2970211A1 (en) Novel protein structure produced by effective antibody used for immunization
JP2022542120A (ja) 抗原性ポリペプチドおよびその使用方法
US20240091346A1 (en) Epstein barr virus vaccines
TW202544252A (zh) 經修飾的CMV類病毒粒子及貓IL-1β突變蛋白抗原之獸醫組成物
JP2022542119A (ja) 抗原性ポリペプチドおよびその使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 AUG 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 AUG 2023